179 related articles for article (PubMed ID: 2434790)
21. Antihypertensive effect of cilazapril in essential hypertensive patients. Clinical study with 24 h ambulatory blood pressure monitoring.
Hiwatari M; Abe K; Yoshinaga K; Saito T
Arzneimittelforschung; 1991 Nov; 41(11):1137-40. PubMed ID: 1839765
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular pressor reactivity after chronic converting enzyme inhibition.
Bernasconi M; Marone C; Beretta-Piccoli C; Lepori G; Shaw S; Weidmann P
Am J Hypertens; 1991 Apr; 4(4 Pt 1):348-55. PubMed ID: 1829371
[TBL] [Abstract][Full Text] [Related]
23. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
[TBL] [Abstract][Full Text] [Related]
24. The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.
Ajayi AA; Elliott HL; Reid JL
Br J Clin Pharmacol; 1986 Aug; 22(2):167-75. PubMed ID: 3019375
[TBL] [Abstract][Full Text] [Related]
25. Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril.
Belz GG; Essig J; Wellstein A
J Cardiovasc Pharmacol; 1987 Feb; 9(2):219-24. PubMed ID: 2436002
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers.
Wellstein A; Essig J; Belz GG
Clin Pharmacol Ther; 1987 Jun; 41(6):639-44. PubMed ID: 3034469
[TBL] [Abstract][Full Text] [Related]
27. Antihypertensive treatment with cilazapril. Resting and exercise blood pressure, hormones and enzymes.
Breithaupt K; Belz GG; Spielmanns DG; Neis W; Kirchner P
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):136-41. PubMed ID: 2159308
[TBL] [Abstract][Full Text] [Related]
28. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.
Gasic S; Heinz G; Kleinbloesem C; Korn A
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):225S-234S. PubMed ID: 2548552
[TBL] [Abstract][Full Text] [Related]
29. Acute effects of cilazapril on coronary hemodynamics in patients with renovascular hypertension.
Magrini F; Reggiani P; Fratianni G; Morganti A; Zanchetti A
J Cardiovasc Pharmacol; 1992; 19 Suppl 5():S128-33. PubMed ID: 1381789
[TBL] [Abstract][Full Text] [Related]
30. Quantitative evidence of peripheral conversion of angiotensin within the human leg: effects of local angiotensin-I administration and angiotensin-converting enzyme inhibition on regional blood flow and angiotensin-II balance across the leg.
Gasic S; Heinz G; Kleinbloesem C
Naunyn Schmiedebergs Arch Pharmacol; 1990 Oct; 342(4):436-40. PubMed ID: 2147739
[TBL] [Abstract][Full Text] [Related]
31. Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor.
Rosendorff C; Patton J; Radford HM; Kalliatakis B
J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S105-9. PubMed ID: 1382157
[TBL] [Abstract][Full Text] [Related]
32. The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.
Essig J; Belz GG; Wellstein A
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):217S-223S. PubMed ID: 2548551
[TBL] [Abstract][Full Text] [Related]
33. A method for estimating the potency of angiotensin-converting enzyme inhibitors in man.
Wellstein A; Essig J; Belz GG
Br J Clin Pharmacol; 1987 Sep; 24(3):397-9. PubMed ID: 2959304
[TBL] [Abstract][Full Text] [Related]
34. Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.
Kleinbloesem CH; Erb K; Essig J; Breithaupt K; Belz GG
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):309S-315S. PubMed ID: 2527544
[TBL] [Abstract][Full Text] [Related]
35. A potent converting enzyme inhibitor CGS 13928C. Drug profile in normal volunteers.
Schaller MD; Brunner DB; Nussberger J; Turini GA; Sen SB; Chen D; Waeber B; Brunner HR
Eur J Clin Pharmacol; 1984; 26(4):419-24. PubMed ID: 6329767
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs.
Holck M; Fischli W; Hefti F; Gerold M
J Cardiovasc Pharmacol; 1986; 8(1):99-108. PubMed ID: 2419701
[TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol.
Erb KA; Essig J; Breithaupt K; Belz GG
Drugs; 1991; 41 Suppl 1():11-7. PubMed ID: 1712266
[TBL] [Abstract][Full Text] [Related]
38. The effect of acute ACE inhibition on atrial natriuretic peptide.
Doorenbos CJ; van Brummelen P
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):243S-247S. PubMed ID: 2527537
[TBL] [Abstract][Full Text] [Related]
39. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system of normal volunteers.
Bussien JP; Nussberger J; Porchet M; Waeber B; Brunner HR; Perisic M; Tansey MJ; Bomm M; Hajdu P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Mar; 329(1):63-9. PubMed ID: 2987705
[TBL] [Abstract][Full Text] [Related]
40. Acute effects of the new angiotensin-converting enzyme inhibitor cilazapril: a pilot study.
Mulinari RA; Gouni I; Gavras I; Gavras H
J Clin Pharmacol; 1988 Jul; 28(7):660-3. PubMed ID: 2975290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
